Quantcast

Latest H5N1 clinical trials Stories

2009-11-02 07:00:00

ROCKVILLE, Md., Nov. 2 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that the Company made a poster presentation on the "Safety and Immunogenicity of a Recombinant Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine in Healthy Adults" on Saturday, October 31, 2009 at the 47(th) Annual Meeting of the Infectious Diseases Society of America (IDSA). This presentation included data from a study of Novavax's trivalent...

a572c7c0094dd102cdace4b01a2b02f71
2009-10-30 15:25:00

World Health Organization officials on Friday announced that one dose of the H1N1 swine flu vaccine is all that is needed to ensure immunity against the virus. The Strategic Advisory Group of Experts (SAGE) on Immunization devoted a session of its October 27-29 meeting to pandemic influenza vaccines. "Items on the agenda included the status of vaccine availability, results from clinical trials on vaccine immunogenicity, and early results from safety monitoring in countries where...

2009-10-22 14:30:00

GAITHERSBURG, Md., Oct. 22 /PRNewswire/ -- MedImmune announced today that interim data from human studies of its nasal spray vaccine for the 2009 novel Influenza A (H1N1) virus demonstrate a similar clinical profile in children and adults 2 to 49 years of age as previously studied seasonal formulations of the vaccine. The live attenuated influenza vaccine (LAIV) for the 2009 novel Influenza A (H1N1) virus received approval from the U.S. Food and Drug Administration (FDA) on September 15,...

2009-10-21 06:30:00

ROCKVILLE, Md. and MARLBOROUGH, Mass., Oct. 21 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) and Xcellerex, Inc. have entered into a strategic collaboration to accelerate the development of Novavax's vaccine manufacturing process to commercial scale and begin immediate production of Novavax's novel 2009 H1N1 influenza vaccine for potential commercial sale. Earlier this week, Novavax launched a two-stage, 4,000-patient clinical study of its H1N1 flu vaccine in Mexico to support...

2009-10-20 03:30:00

ROCKVILLE, Md., Oct. 20 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that it has initiated a two-stage clinical study of its virus-like-particle (VLP) H1N1 influenza vaccine in Mexico in collaboration with Avimex Laboratories (Avimex) and GE Healthcare. Avimex distributes biological and pharmaceutical products for use in Mexico and more than 25 other countries around the world. Avimex is providing financial support for the trial and is expected to...

2009-10-19 16:21:00

SILVER SPRING, Md., Oct. 19 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved use of the seasonal influenza vaccine Fluarix for children ages 3 years to 17 years. Previously, this vaccine, which contains inactivated (killed) influenza A and B viruses, had been approved for use in adults, ages 18 years and older. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) The safety and effectiveness of Fluarix for use in children ages 3 years and older...

2009-10-16 11:00:00

SAYRE, Pa., Oct. 16 /PRNewswire-USNewswire/ -- The Sayre Area School District in Bradford County today became the first Pennsylvania school district to begin administering Novel H1N1 influenza vaccine to its student population, the Department of Health announced. The department also reminded all parents that immunizations play a significant role in keeping children healthy. "The H1N1 virus is disproportionately affecting school-aged children, with almost two-thirds of all cases in...

2009-10-15 08:46:06

Veterinary scientists have made a discovery that promises to deliver a new approach to fast development of cheap vaccines that are effective in all mammals "“ not just humans or another particular species. They propose that by harnessing the system that reads the biological "Ëœbarcodes' of infectious microbes such as food poisoning bacteria, flu viruses and protozoa that cause malaria, one vaccine could be made to prevent a particular disease in all mammals. The research is...

d87e676093a6c7cd8667883edfa4b14a1
2009-10-14 15:35:00

French drugmaker Sanofi-Aventis announced Wednesday that children under the age of 10 may need to get vaccinated twice in order to be protected against the H1N1 swine flu. The announcement falls in line with recommendations from health officials for children in the same age bracket to receive a two-dose regimen in order to protect against the seasonal flu. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told the Associated Press that just one dose of...

2009-10-14 08:01:00

SWIFTWATER, Pa., Oct. 14 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today an interim analysis of data from clinical trials of the U.S. licensed Influenza A (H1N1) 2009 Monovalent Vaccine in infants and children 6 months through 9 years of age. The data indicate the vaccine is immunogenic and that one dose may protect many children. However, the study suggests that two doses of vaccine will be required for...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'